drugset / Trial / NCT06120075
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Timeline
- Start
- 2024-01-19
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB801 | Unknown | — | Oral |
| Subject | Docetaxel | Small molecule | — | Intravenous |
Indications
No indication recorded.